wasn't saying anything about shorts, just making t
Post# of 154922
(Total Views: 602)
Posted On: 01/31/2020 1:51:18 PM
Re: bwolfy2002 #16462
wasn't saying anything about shorts, just making the point that there are folks out there following us....
here's part of his comments:
"Here’s the next penny stock to watch in February 2020…
CytoDyn Inc (OTCQB: CYDY)
CytoDyn was on my watchlist for January, as well. It just keeps going — showing a pattern of a few green days followed by several days of consolidation. Like CNBX, CYDY had a near-perfect breakout. Also trading on higher than average volume, the stock is already at multi-year highs.
CytoDyn is a clinical-stage biotech company based in the U.S. It focuses on therapies for HIV and cancer. Its primary late-stage product, Leronmilab, blocks HIV from entering and infecting certain cells.
On December 18, CytoDyn announced a deal to license the U.S. rights to leronlimab for the treatment of HIV. On December 23, it announced positive clinical results for a breast cancer treatment.
The stock broke out again after a January 28 press release. Leronlimab is under evaluation for treating the coronavirus. For more on the coronavirus emergency read this: Wuhan Coronavirus: 9 Stocks to Watch.
Take a look at the CYDY six-month chart:"
here's part of his comments:
"Here’s the next penny stock to watch in February 2020…
CytoDyn Inc (OTCQB: CYDY)
CytoDyn was on my watchlist for January, as well. It just keeps going — showing a pattern of a few green days followed by several days of consolidation. Like CNBX, CYDY had a near-perfect breakout. Also trading on higher than average volume, the stock is already at multi-year highs.
CytoDyn is a clinical-stage biotech company based in the U.S. It focuses on therapies for HIV and cancer. Its primary late-stage product, Leronmilab, blocks HIV from entering and infecting certain cells.
On December 18, CytoDyn announced a deal to license the U.S. rights to leronlimab for the treatment of HIV. On December 23, it announced positive clinical results for a breast cancer treatment.
The stock broke out again after a January 28 press release. Leronlimab is under evaluation for treating the coronavirus. For more on the coronavirus emergency read this: Wuhan Coronavirus: 9 Stocks to Watch.
Take a look at the CYDY six-month chart:"
(1)
(0)